SALT LAKE CITY, Nov. 04, 2016 (GLOBE NEWSWIRE) -- Assurex Health, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ:MYGN), today announced that a poster featuring the GeneSight ® test will be presented at the Neuroscience Education Institute (NEI) Psychopharmacology Congress being held Nov. 3-6, 2016 in Colorado Springs, Colo. In this subanalysis of a previously published study, patients with generalized anxiety disorder (GAD) experienced significant cost savings when decisions congruent with the GeneSight report were made by healthcare providers. In the previously published study, congruency with the GeneSight test was shown to deliver significant cost savings for patients with major depressive disorder (MDD). "We believe that GeneSight has the potential to improve outcomes for patients being treated with psychotropic drugs and eliminate a significant amount of waste in our healthcare system," said Bryan M. Dechairo, Ph.D., chief medical and science officer, Assurex Health. "We look forward to sharing these data with the medical community and payers." Below is a summary of the featured presentation at NEI (#NEI2016). Poster PresentationTitle: GeneSight Psychotropic Decreases Medication Costs for Patients with Anxiety and Bipolar Disorders in a Large, Prospective Case-Control Project Presenter: Kim Horn. Date: Friday, Nov. 4, 2016: 6:00-7:30 p.m. MT. This study assessed the economic utility of the GeneSight test for 318 patients with generalized anxiety disorder (GAD) when healthcare providers made decisions congruent with the GeneSight test report. Patients in the GeneSight-guided group of the previously published study were subdivided into two groups. The first group included patients whose healthcare provider made treatment decisions congruent with the GeneSight test report. The second group included patients whose provider made treatment decisions incongruent with the test report. The analysis compared total medication costs between the congruent and incongruent groups for patients based on their diagnosis of GAD.